Compare Stocks: JFU, THAR, UPXI, and HYPD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HYPD Hyperion DeFi	$3.72 -0.6%	$3.19	$2.34 ▼ $11.89	$57.75M	2.53	471,569 shs	193,499 shs
JFU 9F	$2.85 +1.3%	$2.55	$1.98 ▼ $9.48	$33.50M	1.16	3,746 shs	712 shs
THAR Tharimmune	$2.38 -0.2%	$2.13	$0.95 ▼ $9.08	$89.61M	1.43	1.48 million shs	446,132 shs
UPXI Upexi	$1.16 +1.3%	$0.98	$0.54 ▼ $7.75	$94.83M	-0.21	3.80 million shs	1.83 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HYPD Hyperion DeFi	-6.27%	-4.59%	+9.36%	+20.26%	-60.96%
JFU 9F	+1.80%	+0.54%	-4.97%	+8.40%	+3.93%
THAR Tharimmune	-11.52%	-2.86%	+7.21%	-19.05%	-16.20%
UPXI Upexi	-0.87%	-2.56%	+4.59%	+29.55%	-80.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HYPD Hyperion DeFi	$3.72 -0.6%	$3.19	$2.34 ▼ $11.89	$57.75M	2.53	471,569 shs	193,499 shs
JFU 9F	$2.85 +1.3%	$2.55	$1.98 ▼ $9.48	$33.50M	1.16	3,746 shs	712 shs
THAR Tharimmune	$2.38 -0.2%	$2.13	$0.95 ▼ $9.08	$89.61M	1.43	1.48 million shs	446,132 shs
UPXI Upexi	$1.16 +1.3%	$0.98	$0.54 ▼ $7.75	$94.83M	-0.21	3.80 million shs	1.83 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HYPD Hyperion DeFi	-6.27%	-4.59%	+9.36%	+20.26%	-60.96%
JFU 9F	+1.80%	+0.54%	-4.97%	+8.40%	+3.93%
THAR Tharimmune	-11.52%	-2.86%	+7.21%	-19.05%	-16.20%
UPXI Upexi	-0.87%	-2.56%	+4.59%	+29.55%	-80.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HYPD Hyperion DeFi	2.25	Hold	$9.83	164.40% Upside
JFU 9F	1.00	Sell	N/A	N/A
THAR Tharimmune	1.00	Sell	N/A	N/A
UPXI Upexi	2.00	Hold	$5.00	332.90% Upside

Current Analyst Ratings Breakdown

Latest JFU, THAR, UPXI, and HYPD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$2.00
9/10/2026	HYPD Hyperion DeFi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$7.10 ➝ $11.20
9/10/2026	HYPD Hyperion DeFi	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/10/2026	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1.30 ➝ $2.00
9/8/2026	HYPD Hyperion DeFi	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.30 ➝ $8.45
9/4/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/1/2026	HYPD Hyperion DeFi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/21/2026	JFU 9F	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/18/2026	HYPD Hyperion DeFi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/13/2026	HYPD Hyperion DeFi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$6.60 ➝ $7.10
8/12/2026	HYPD Hyperion DeFi	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HYPD Hyperion DeFi	$810K	71.29	N/A	N/A	$4.73 per share	0.79
JFU 9F	$41.45M	0.81	$2.24 per share	1.27	$45.81 per share	0.06
THAR Tharimmune	N/A	N/A	N/A	N/A	$0.68 per share	N/A
UPXI Upexi	$25M	3.79	N/A	N/A	($0.68) per share	-1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HYPD Hyperion DeFi	-$45.31M	-$6.53	N/A	3.75	N/A	416.56%	-11.62%	-9.96%	N/A
JFU 9F	$24.05M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
THAR Tharimmune	-$12.20M	-$3.99	N/A	N/A	N/A	N/A	-588.45%	-264.41%	N/A
UPXI Upexi	-$246.07M	-$4.06	N/A	N/A	N/A	-984.34%	-157.49%	-22.60%	11/11/2026 (Estimated)

Latest JFU, THAR, UPXI, and HYPD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/17/2026	Q4 2026	UPXI Upexi	-$0.11	-$0.10	+$0.01	-$2.20	$5.80 million	$6.52 million
8/13/2026	Q2 2026	HYPD Hyperion DeFi	N/A	$0.92	N/A	$0.92	N/A	$0.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
JFU 9F	N/A	N/A	N/A	N/A	N/A
THAR Tharimmune	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HYPD Hyperion DeFi	0.06	2.34	2.34
JFU 9F	N/A	7.46	7.46
THAR Tharimmune	N/A	4.98	4.98
UPXI Upexi	2.96	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HYPD Hyperion DeFi	25.84%
JFU 9F	N/A
THAR Tharimmune	1.16%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
HYPD Hyperion DeFi	7.50%
JFU 9F	53.90%
THAR Tharimmune	6.70%
UPXI Upexi	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HYPD Hyperion DeFi	9	15.54 million	14.37 million	No Data
JFU 9F	185	11.77 million	5.43 million	Not Optionable
THAR Tharimmune	2	37.73 million	35.20 million	Not Optionable
UPXI Upexi	59	82.10 million	74.71 million	Optionable

JFU, THAR, UPXI, and HYPD Headlines

Recent News About These Companies

Upexi Earnings Call: High-Stakes Bet on Solana

September 22, 2026 | tipranks.com

UPEXI (NASDAQ: UPXI) Reports $25M Revenue, $246M Net Loss, Highlights Growth in Digital Asset Revenue

September 20, 2026 | kalkinemedia.comK

Cantor Fitzgerald Reiterates "Overweight" Rating for Upexi (NASDAQ:UPXI)

September 20, 2026 | americanbankingnews.com

Upexi (NASDAQ:UPXI) Lowered to Sell Rating by Wall Street Zen

September 20, 2026 | americanbankingnews.com

Upexi (NASDAQ:UPXI) Stock Rating Lowered by Wall Street Zen

September 20, 2026 | marketbeat.com

Analysts Offer Insights on Communication Services Companies: Upexi (UPXI) and AT&T (T)

September 19, 2026 | theglobeandmail.com

Upexi expects staking revenue to more than cover ongoing cash expenses as it cuts headcount to 10 and refinances debt to 7.5%

September 18, 2026 | seekingalpha.com

Upexi (UPXI) Q4 2026 Earnings Call Transcript

September 18, 2026 | finance.yahoo.com

Upexi Target of Unusually Large Options Trading (NASDAQ:UPXI)

September 18, 2026 | marketbeat.com

Upexi (NASDAQ:UPXI) Receives Overweight Rating from Cantor Fitzgerald

September 18, 2026 | marketbeat.com

Upexi Q4 Earnings Call Highlights

September 17, 2026 | marketbeat.com

Upexi (UPXI) Stock Falls on Quarterly Earnings

September 17, 2026 | quiverquant.comQ

Upexi Reports Fiscal 2026 Results, Digital Asset Revenue of $17.4 Million and 2.34 Million SOL Held at Year-End

September 17, 2026 | quiverquant.comQ

Upexi Reports Financial Results for Fiscal Year Ended June 30, 2026

September 17, 2026 | globenewswire.com

Upexi to Host Fiscal Year 2026 Earnings Call on Thursday, September 17th at 5:30 P.M. ET

September 15, 2026 | globenewswire.com

Upexi Amends BitGo Credit Facility

September 14, 2026 | globenewswire.com

Wall Street Zen Upgrades Upexi (NASDAQ:UPXI) to "Hold"

September 12, 2026 | marketbeat.com

Cantor Fitzgerald Boosts Upexi (NASDAQ:UPXI) Price Target to $2.00

September 10, 2026 | marketbeat.com

Upexi to Participate in FT Partners FinTech Conference 2026 on September 15th

September 8, 2026 | globenewswire.com

Upexi Faces Nasdaq Non-Compliance on Minimum Bid Price

July 31, 2026 | tipranks.com

Upexi Insider Trading Activity | NASDAQ:UPXI | Benzinga

July 7, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JFU, THAR, UPXI, and HYPD Company Descriptions

Hyperion DeFi NASDAQ:HYPD

$3.72 -0.02 (-0.59%)

As of 03:14 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

9F NASDAQ:JFU

$2.85 +0.04 (+1.28%)

As of 02:19 PM Eastern

9F Inc., together with its subsidiaries, operates internet securities service platform in the People's Republic of China. The company operates through three segments: Technology Empowerment Services, E-commerce business, and Wealth Management. Its products include digital financial accounts that offer online lending, wealth management, and payment facilitation services; revolving and non-revolving loan products to borrowers, as well as traffic referral services to financial institution partners; and a suite of online wealth management products, such as fixed income products, stocks, insurance, bank wealth management products, and mutual funds to investors in various platforms, including Wukong Licai, 9F Wallet, and 9F Puhui. The company also provides payment facilitation and other products and services that help users to pay credit card bills and household bills comprising utility bills; and other value-added services consisting of credit history search, debt consolidation, and user referral services. In addition, it offers technology empowerment services to banking, automobile, securities investment, and insurance industries; and engages in E-commerce business, which offers various categories of merchandise, including 3C products, beauty and skin care products, food, household appliances, and liquor and beverages. It provides its services to borrowers, investors, and financial institutions partners. The company was formerly known as JIUFU Financial Technology Service Limited and changed its name to 9F Inc. in June 2014. 9F Inc. was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

Tharimmune NASDAQ:THAR

$2.38 -0.01 (-0.21%)

As of 09/30/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Upexi NASDAQ:UPXI

$1.16 +0.02 (+1.32%)

As of 03:14 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JFU, THAR, UPXI, and HYPD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JFU, THAR, UPXI, and HYPD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JFU, THAR, UPXI, and HYPD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JFU, THAR, UPXI, and HYPD Company Descriptions

Hyperion DeFi NASDAQ:HYPD

9F NASDAQ:JFU

Tharimmune NASDAQ:THAR

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JFU, THAR, UPXI, and HYPD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JFU, THAR, UPXI, and HYPD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JFU, THAR, UPXI, and HYPD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JFU, THAR, UPXI, and HYPD Company Descriptions

Hyperion DeFi NASDAQ:HYPD

9F NASDAQ:JFU

Tharimmune NASDAQ:THAR

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools